Tyra Biosciences, Inc. (TYRA)
TYRANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$22.30
+1.15 (+5.44%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.53bn
- P/E
- –
- EPS, last 4 quarters
- $-2.40
- Dividend yield
- –
- Day range
- –
- 52-week range
- $13.83 to $40.65
- Average volume
- 933.4k
- Previous close
- $21.15
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $48.00, +115.2% from here
Earnings
next estimate $-0.6600Next report Nov 11, 2026
Sep 2025
0.0%
Dec 2025
-5.6%
Mar 2026
-6.7%
Jun 2026
-3.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$32.94m | -$36.52m | -$42.00m | -$49.00m |
| Net income | -$29.87m | -$33.83m | -$39.30m | -$45.56m |
News
8 latest- Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 WeeksZacks · Oct 14, 2026
- Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains RTTNews · Sep 14, 2026
- Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3 RTTNews · Sep 14, 2026
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- Tyra Biosciences Reports Positive SURF302 Results; Plans Phase 3 In LG IR NMIBC RTTNews · Sep 9, 2026
- Noteworthy Friday Option Activity: TYRA, CLYM, AVBPBNK Invest · Sep 4, 2026
- Wolfe Research Initiates Coverage of Tyra Biosciences (TYRA) with Peer Perform RecommendationFintel · May 19, 2026
- Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesThe Motley Fool · May 17, 2026
The company
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low grade upper tract urothelial cancer, low grade intermediate risk non-muscle invasive bladder cancer and achondroplasia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- tyra.bio
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.